Tirzepatide · research summary

Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists.

Frontiers in endocrinology · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Narrative and analytical review synthesizing primary literature on incretin and multi-receptor agonist therapies.
“This is a narrative and analytical review.”

Subjects

Adults with cardiometabolic indications including type 2 diabetes, obesity, heart failure, obstructive sleep apnea, and metabolic-dysfunction-associated steatohepatitis.
“The review covers adults with cardiometabolic indications.”

Reported findings

Real-world persistence of therapy is approximately one-third at 12 months in non-diabetic obesity, with discontinuation dominated by cost rather than therapeutic failure.
“Real-world persistence is approximately one-third at 12 months in non-diabetic obesity. Discontinuation is dominated by cost rather than therapeutic failure.”
Weight and cardiometabolic gains revert toward baseline within months of abrupt cessation, and cyclical use is a common real-world pattern.
“Weight and cardiometabolic gains revert toward baseline within months of abrupt cessation. Cyclical use has emerged as a common real-world pattern among adults who discontinue and then restart therapy.”
A substantial fraction of the cardiovascular benefit provided by these therapies is weight independent.
“A substantial fraction of the cardiovascular benefit is weight independent.”

Limitations stated by the authors

Evidence is thin for pediatric and adolescent populations, pregnancy and lactation, and the bariatric-postoperative setting; durability of benefit beyond 1 to 2 years for hepatic, OSA, and HFpEF indications is not yet defined.
“Pediatric and adolescent populations (23), pregnancy and lactation, and the bariatric-postoperative setting are acknowledged gaps where the evidence base is too thin for synthesis here.”

Source: PubMed 42851902 · DOI 10.3389/fendo.2026.1902185 · all study summaries

Reported findings

Real-world persistence of therapy is approximately one-third at 12 months in non-diabetic obesity, with discontinuation dominated by cost rather than therapeutic failure.

“Real-world persistence is approximately one-third at 12 months in non-diabetic obesity. Discontinuation is dominated by cost rather than therapeutic failure.”

Weight and cardiometabolic gains revert toward baseline within months of abrupt cessation, and cyclical use is a common real-world pattern.

“Weight and cardiometabolic gains revert toward baseline within months of abrupt cessation. Cyclical use has emerged as a common real-world pattern among adults who discontinue and then restart therapy.”

A substantial fraction of the cardiovascular benefit provided by these therapies is weight independent.

“A substantial fraction of the cardiovascular benefit is weight independent.”

Limitations stated by the authors

Evidence is thin for pediatric and adolescent populations, pregnancy and lactation, and the bariatric-postoperative setting; durability of benefit beyond 1 to 2 years for hepatic, OSA, and HFpEF indications is not yet defined.

“Pediatric and adolescent populations (23), pregnancy and lactation, and the bariatric-postoperative setting are acknowledged gaps where the evidence base is too thin for synthesis here.”